01 · Process stage
PlannedSynthetic route assessment
Define the chemical reaction steps, necessary reagents and the parameters for primary synthesis.
Capabilities · Drug substance & biological inputs
Small-molecule active ingredients
A proposed service scope for active pharmaceutical ingredients, connecting chemical synthesis, isolation, directed purification and final physical characterisation.
PlannedCatalogue scope
Service statusPlanned
Planned.
Technical boundaries and readiness need confirmation before an activity could be presented as available.
Basis · Catalogue scope
- Status
- PlannedNo available service asserted
- Source-plan relationship
- Catalogue scopeProposed catalogue expansion
- Readiness
- Not establishedProduct and process evidence needed
- Facility roadmap
- First commercial batch target Q1 2028 · indicativeNot a service date
01 · Proposed service scope
Start with the product and its container.
Small-molecule active ingredient processing is presented as a planned service domain. The exact chemical entity, synthesis route and physical target profile would define its eventual scope.
The proposed services catalogue adds small-molecule synthesis as a potential expansion. It lies completely outside the initial Boten project plan and would require separate scope confirmation.
Synthetic chemistry and final physical powder processing represent distinct technical subjects. Expanding a proposed catalogue does not establish that any given reactor train could accommodate a specific synthetic sequence.
Catalogue boundary
A planned catalogue for scoped evaluation. Inclusion does not establish installed, qualified, licensed or available capability.
02 · Presentation families
Match the route to the format.
| Format | Planning note | Basis | Status |
|---|---|---|---|
| Synthetic active ingredients | Proposed small-molecule synthesis is an extension requiring separate confirmation before advancing. | Catalogue scope | Planned |
| Isolated intermediate compoundsPreformulation & formulation development | Chemical intermediates would need appropriate process evaluation and defined analytical boundaries. | Catalogue scope | Planned |
| Highly potent materialsHighly potent & cytotoxic products | Potent compounds demand dedicated containment strategies and separate occupational exposure assessments. | Catalogue scope | Planned |
03 · Process scope for discussion
Make the sequence and its evidence visible.
02 · Process stage
PlannedReaction and transformation
Consider the required thermal controls, atmosphere requirements and specific chemical conversions during synthesis.
03 · Process stage
PlannedIsolation and extraction
Identify the intended solvent systems, phase separations and physical isolation steps for the compound.
04 · Process stage
PlannedPurification and crystallisation
Define the specific chromatographic steps or controlled crystallisation methods required to isolate the active molecule.
05 · Process stage
PlannedDrying and milling
Consider the thermal drying requirements, physical sizing steps and any final powder handling needs.
06 · Process stage
PlannedTesting and release
Connect the batch record to precise analytical evaluation for chemical identity, purity and physical properties.
Illustrative sequence
This is a technical discussion structure, not an operating procedure, approved process flow or representation of installed equipment.
04 · Supporting services
No service stands alone.
01PlannedCatalogue scope
Highly potent & cytotoxic products
Dedicated risk, containment and facility-segregation assessment.
Explore proposed scope02PlannedCatalogue scope
Raw-material & finished-product testing
Material identity, specifications and product-specific test scope.
Explore proposed scope03PlannedCatalogue scope
Preformulation & formulation development
Material properties, formulation options and product-specific development questions.
Explore proposed scope05 · Readiness questions
A service claim needs a defined evidence base.
- Chemical process definition
- Exact synthesis route, intermediate stability profiles and the required reaction parameters.
- Facility qualification
- Relevant installed reactor trains, solvent handling systems and an approved containment model.
- Purification evidence
- Established downstream processing parameters, impurity clearance data and defined residual limits.
- Quality accountability
- Controlled testing boundaries, analytical method scope, review and formal decision rights.
- Regulatory permissions
- Applicable environmental and chemical processing approvals for the intended active ingredient activity.
- Technical agreement
- Responsibilities, disclosure boundaries and defined limits for any future chemical synthesis engagement.
06 · Practical questions
Before a technical discussion.
Is this service currently available?
No. The service is Planned. This page is a scope proposal and does not establish an operating active pharmaceutical ingredient synthesis service.
Does this synthesis belong to the initial Boten plan?
No. The initial plan focuses on injectable presentations and protein raw materials. Small-molecule active ingredients represent a proposed expansion requiring separate scope confirmation.
What information helps define the question?
Identify the proposed chemical entity, synthesis stage, intended destination and the technical question. Confidential data should only be shared through an agreed route.
Is there a service launch quarter?
No. No service-specific quarter is established. The project-wide indicative milestones do not commit any individual domain to a start date.
Does a technical discussion establish supply?
No. Feasibility, scope, regulatory permissions, analytical evidence and a technical agreement would need to be established before a supply commitment.
Professional enquiries
Discuss a defined question.
Describe the presentation, development question and destination relevant to the proposed scope. Do not infer service availability from this planning page.